These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25907335)

  • 1. IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.
    Reid TJ; Jin Z; Shen W; Reyes-Vidal CM; Fernandez JC; Bruce JN; Kostadinov J; Post KD; Freda PU
    Pituitary; 2015 Dec; 18(6):808-19. PubMed ID: 25907335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.
    Reyes-Vidal C; Fernandez JC; Bruce JN; Crisman C; Conwell IM; Kostadinov J; Geer EB; Post KD; Freda PU
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4124-32. PubMed ID: 25137427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.
    Lin E; Wexler TL; Nachtigall L; Tritos N; Swearingen B; Hemphill L; Loeffler J; Biller BM; Klibanski A; Miller KK
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):430-8. PubMed ID: 22315983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.
    Hansen TB; Gram J; Bjerre P; Hagen C; Bollerslev J
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):323-9. PubMed ID: 7955439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly.
    Ueland T; Fougner SL; Godang K; Lekva T; Schurgers LJ; Scholz H; Halvorsen B; Schreiner T; Aukrust P; Bollerslev J
    J Clin Endocrinol Metab; 2010 Jan; 95(1):361-8. PubMed ID: 19880791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.
    Niculescu D; Purice M; Coculescu M
    Pituitary; 2013 Jun; 16(2):168-74. PubMed ID: 22562529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
    Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
    Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.
    Freda PU; Shen W; Heymsfield SB; Reyes-Vidal CM; Geer EB; Bruce JN; Gallagher D
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2334-43. PubMed ID: 18349062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
    Puder JJ; Nilavar S; Post KD; Freda PU
    J Clin Endocrinol Metab; 2005 Apr; 90(4):1972-8. PubMed ID: 15634715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study.
    Wolf P; Salenave S; Durand E; Young J; Kamenicky P; Chanson P; Maione L
    Eur J Endocrinol; 2021 Dec; 186(2):173-181. PubMed ID: 34792486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin secretion and insulin-like growth factor-I levels in active and controlled acromegaly.
    Hopkins KD; Holdaway IM
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):53-7. PubMed ID: 1559300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
    Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
    Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible insulin resistance in muscle and fat unrelated to the metabolic syndrome in patients with acromegaly.
    Arlien-Søborg MC; Dal J; Madsen MA; Høgild ML; Hjelholt AJ; Pedersen SB; Møller N; Jessen N; Jørgensen JOL
    EBioMedicine; 2022 Jan; 75():103763. PubMed ID: 34929488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.
    Bredella MA; Schorr M; Dichtel LE; Gerweck AV; Young BJ; Woodmansee WW; Swearingen B; Miller KK
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4218-4225. PubMed ID: 28945897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased GH/IGF-I Axis Activity Relates to Lower Hepatic Lipids and Phosphor Metabolism.
    Fellinger P; Beiglböck H; Semmler G; Pfleger L; Smajis S; Baumgartner C; Gajdosik M; Marculescu R; Vila G; Winhofer Y; Scherer T; Trauner M; Kautzky-Willer A; Krssak M; Krebs M; Wolf P
    J Clin Endocrinol Metab; 2023 Sep; 108(10):e989-e997. PubMed ID: 37104943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.